ViewRay Stock

ViewRay Current Liabilities

The Current Liabilities of ViewRay (VRAYQ) as of Sep 3, 2026 is 81.68 M USD. In the previous year, Current Liabilities was 72.74 M USD — a change of 12.29% (higher).

Current Liabilities

81.68 MUSD

YoY

12.29%

Last updated:

Current Liabilities of ViewRay is 2026 81.68 M USD. Current Liabilities of ViewRay was 2025 72.74 M USD. It decreases by 12.29% higher compared to the previous year.

The ViewRay Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2015
14.95 M USD
Jan 1, 2016
17.60 M USD
Jan 1, 2017
25.27 M USD
Jan 1, 2018
29.41 M USD
Jan 1, 2019
63.18 M USD
Jan 1, 2020
51.36 M USD
Jan 1, 2021
72.74 M USD
Jan 1, 2022
81.68 M USD
The ViewRay Current Liabilities history
YEARCurrent LiabilitiesYoY
81.68 MUSD+12.29%
72.74 MUSD+41.64%
51.36 MUSD-18.72%
63.18 MUSD+114.85%
29.41 MUSD+16.37%
25.27 MUSD+43.58%
17.60 MUSD+17.72%
14.95 MUSD+50.92%
9.91 MUSD+147.51%
4.00 MUSD-59.78%
9.95 MUSD
Access this data via the Eulerpool API

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViewRay stock

Current Liabilities of ViewRay is 81.68 M USD in 2026.

Current Liabilities of ViewRay changed from 72.74 M USD to 81.68 M USD, representing a 12.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities ViewRay since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's ViewRay historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ViewRay

All Key Metrics — ViewRay